MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in scPharmaceuticals Inc. (NASDAQ:SCPH) by 36.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,973 shares of the company’s stock after acquiring an additional 5,827 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in scPharmaceuticals were worth $78,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Legato Capital Management LLC acquired a new position in scPharmaceuticals in the fourth quarter valued at $37,000. China Universal Asset Management Co. Ltd. acquired a new position in scPharmaceuticals in the fourth quarter valued at $38,000. Price T Rowe Associates Inc. MD acquired a new position in scPharmaceuticals in the fourth quarter valued at $54,000. Wells Fargo & Company MN increased its stake in scPharmaceuticals by 110.5% in the fourth quarter. Wells Fargo & Company MN now owns 18,407 shares of the company’s stock valued at $65,000 after purchasing an additional 9,663 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in scPharmaceuticals in the fourth quarter valued at $66,000. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

scPharmaceuticals Stock Performance

Shares of NASDAQ:SCPH opened at $3.84 on Tuesday. The firm has a market capitalization of $202.72 million, a PE ratio of -2.02 and a beta of 0.17. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The business has a 50-day moving average of $2.70 and a two-hundred day moving average of $3.12. scPharmaceuticals Inc. has a 12 month low of $1.94 and a 12 month high of $5.65.

scPharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.06). scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The firm had revenue of $11.75 million for the quarter, compared to analyst estimates of $11.63 million. As a group, research analysts forecast that scPharmaceuticals Inc. will post -1.53 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have commented on SCPH. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a research note on Thursday, March 20th. Maxim Group dropped their price target on scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, March 20th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.